{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T17:55:20Z","timestamp":1795283720774,"version":"4.10.3"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2024,8,1]]},"abstract":"<jats:sec id=\"ab-eoi240035-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Anecdotal experience raised the possibility that semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA) with rapidly increasing use, is associated with nonarteritic anterior ischemic optic neuropathy (NAION).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240035-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To investigate whether there is an association between semaglutide and risk of NAION.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240035-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>\n                      In a retrospective matched cohort study using data from a centralized data registry of patients evaluated by neuro-ophthalmologists at 1 academic institution from December 1, 2017, through November 30, 2023, a search for\n                      <jats:italic>International Statistical Classification of Diseases and Related Health Problems, Tenth Revision<\/jats:italic>\n                      code H47.01 (ischemic optic neuropathy) and text search yielded 16\u202f827 patients with no history of NAION. Propensity matching was used to assess whether prescribed semaglutide was associated with NAION in patients with type 2 diabetes (T2D) or overweight\/obesity, in each case accounting for covarying factors (sex, age, systemic hypertension, T2D, obstructive sleep apnea, obesity, hyperlipidemia, and coronary artery disease) and contraindications for use of semaglutide. The cumulative incidence of NAION was determined with the Kaplan-Meier method and a Cox proportional hazards regression model adjusted for potential confounding comorbidities. Data were analyzed from December 1, 2017, through November 30, 2023.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240035-7\">\n                    <jats:title>Exposures<\/jats:title>\n                    <jats:p>Prescriptions for semaglutide vs non\u2013GLP-1 RA medications to manage either T2D or weight.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240035-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Cumulative incidence and hazard ratio of NAION.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240035-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 16\u202f827 patients, 710 had T2D (194 prescribed semaglutide; 516 prescribed non\u2013GLP-1 RA antidiabetic medications; median [IQR] age, 59 [49-68] years; 369 [52%] female) and 979 were overweight or obese (361 prescribed semaglutide; 618 prescribed non\u2013GLP-1 RA weight-loss medications; median [IQR] age, 47 [32-59] years; 708 [72%] female). In the population with T2D, 17 NAION events occurred in patients prescribed semaglutide vs 6 in the non\u2013GLP-1 RA antidiabetes cohort. The cumulative incidence of NAION for the semaglutide and non\u2013GLP-1 RA cohorts over 36 months was 8.9% (95% CI, 4.5%-13.1%) and 1.8% (95% CI, 0%-3.5%), respectively. A Cox proportional hazards regression model showed higher risk of NAION for patients receiving semaglutide (hazard ratio [HR], 4.28; 95% CI, 1.62-11.29);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001). In the population of patients who were overweight or obese, 20 NAION events occurred in the prescribed semaglutide cohort vs 3 in the non\u2013GLP-1 RA cohort. The cumulative incidence of NAION for the semaglutide vs non\u2013GLP-1 RA cohorts over 36 months was 6.7% (95% CI, 3.6%-9.7%) and 0.8% (95% CI, 0%-1.8%), respectively. A Cox proportional hazards regression model showed a higher risk of NAION for patients prescribed semaglutide (HR, 7.64; 95% CI, 2.21-26.36;\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&amp;amp;lt;\u2009.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-eoi240035-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>This study\u2019s findings suggest an association between semaglutide and NAION. As this was an observational study, future study is required to assess causality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamaophthalmol.2024.2296","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:09:44Z","timestamp":1720004984000},"page":"732","source":"Crossref","is-referenced-by-count":343,"title":["Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide"],"prefix":"10.1001","volume":"142","author":[{"given":"Jimena Tatiana","family":"Hathaway","sequence":"first","affiliation":[{"name":"Harvard T.H. Chan School of Public Health, Boston, Massachusetts"},{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhura P.","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David B.","family":"Hathaway","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyedeh Maryam","family":"Zekavat","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drenushe","family":"Krasniqi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John W.","family":"Gittinger","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Cestari","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Mallery","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardia","family":"Abbasi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Bouffard","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart K.","family":"Chwalisz","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tais","family":"Estrela","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Joseph F.","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston"},{"name":"Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"4","key":"eoi240035r1","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/brain\/98.4.689","article-title":"Ischaemic optic neuropathy: the clinical profile and history.","volume":"98","author":"Boghen","year":"1975","journal-title":"Brain"},{"issue":"1","key":"eoi240035r2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/00041327-199403000-00011","article-title":"Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy: population-based study in the state of Missouri and Los Angeles County, California.","volume":"14","author":"Johnson","year":"1994","journal-title":"J Neuroophthalmol"},{"issue":"12","key":"eoi240035r3","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1016\/j.ophtha.2016.08.017","article-title":"Demographic, systemic, and ocular factors associated with nonarteritic anterior ischemic optic neuropathy.","volume":"123","author":"Cestari","year":"2016","journal-title":"Ophthalmology"},{"issue":"11","key":"eoi240035r4","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1001\/archopht.123.11.1554","article-title":"Visual field abnormalities in nonarteritic anterior ischemic optic neuropathy: their pattern and prevalence at initial examination.","volume":"123","author":"Hayreh","year":"2005","journal-title":"Arch Ophthalmol"},{"issue":"12","key":"eoi240035r6","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ijsu.2014.07.013","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"12","author":"von Elm","year":"2014","journal-title":"Int J Surg"},{"issue":"12","key":"eoi240035r7","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1001\/archopht.1991.01080120052024","article-title":"Optic neuritis and ischemic optic neuropathy: overlapping clinical profiles.","volume":"109","author":"Rizzo","year":"1991","journal-title":"Arch Ophthalmol"},{"key":"eoi240035r8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide.","volume":"12","author":"Smits","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"eoi240035r9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.urology.2017.02.044","article-title":"Prospective case-crossover study investigating the possible association between nonarteritic anterior ischemic optic neuropathy and phosphodiesterase type 5 inhibitor exposure.","volume":"105","author":"Flahavan","year":"2017","journal-title":"Urology"},{"issue":"2","key":"eoi240035r10","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/S0025-6196(12)64959-3","article-title":"Amiodarone-related optic neuropathy.","volume":"63","author":"Gittinger","year":"1988","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"eoi240035r11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/eye.2014.144","article-title":"Current concepts in the diagnosis, pathogenesis and management of nonarteritic anterior ischaemic optic neuropathy.","volume":"29","author":"Miller","year":"2015","journal-title":"Eye (Lond)"},{"issue":"3","key":"eoi240035r12","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/archopht.117.3.386","article-title":"Nonarteritic anterior ischemic optic neuropathy: enigma variations.","volume":"117","author":"Lessell","year":"1999","journal-title":"Arch Ophthalmol"},{"issue":"4","key":"eoi240035r13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/WNO.0000000000000870","article-title":"Unraveling the enigma of nonarteritic anterior ischemic optic neuropathy.","volume":"39","author":"Rizzo","year":"2019","journal-title":"J Neuroophthalmol"},{"issue":"1","key":"eoi240035r14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","article-title":"Incidence of nonarteritic anterior ischemic optic neuropathy.","volume":"123","author":"Hattenhauer","year":"1997","journal-title":"Am J Ophthalmol"},{"issue":"15","key":"eoi240035r16","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2017.14752","article-title":"Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes: a randomized clinical trial.","volume":"318","author":"Davies","year":"2017","journal-title":"JAMA"},{"key":"eoi240035r17","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-3-030-51089-3","article-title":"Effects of GLP-1 and its analogs on gastric physiology in diabetes mellitus and obesity.","volume":"1307","author":"Maselli","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"eoi240035r18","doi-asserted-by":"publisher","first-page":"d7771","DOI":"10.1136\/bmj.d7771","article-title":"Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.","volume":"344","author":"Vilsb\u00f8ll","year":"2012","journal-title":"BMJ"},{"issue":"24","key":"eoi240035r19","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"19","key":"eoi240035r20","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"11","key":"eoi240035r21","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity.","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"eoi240035r22","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1111\/dom.2018.20.issue-4","article-title":"Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy.","volume":"20","author":"Vilsb\u00f8ll","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"eoi240035r23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ajo.2024.04.010","article-title":"Impact of GLP-1 agonists and SGLT-2 inhibitors on diabetic retinopathy progression: an aggregated electronic health record data study.","volume":"265","author":"Wai","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"eoi240035r24","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review.","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"issue":"1","key":"eoi240035r25","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.v8.1","article-title":"Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.","volume":"8","author":"N\u00f8rgaard","year":"2022","journal-title":"Alzheimers Dement (N Y)"},{"issue":"9","key":"eoi240035r26","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1111\/dom.2018.20.issue-9","article-title":"Glucagon-like peptide-1 receptor expression in the human eye.","volume":"20","author":"Hebsgaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"eoi240035r27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/oby.v32.3","article-title":"Early- and later-stage persistence with antiobesity medications: a retrospective cohort study.","volume":"32","author":"Gasoyan","year":"2024","journal-title":"Obesity (Silver Spring)"},{"key":"eoi240035r29","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ajo.2023.03.013","article-title":"Race distribution in nonarteritic anterior ischemic optic neuropathy.","volume":"253","author":"Banc","year":"2023","journal-title":"Am J Ophthalmol"},{"key":"eoi240035r30","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ajo.2023.04.009","article-title":"Comment on \u201cRace distribution in non-arteritic anterior ischemic optic neuropathy\u201d.","volume":"252","author":"Wagner","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"eoi240035r31","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/WNO.0000000000000971","article-title":"Validity of International Classification of Diseases codes for identifying neuro-ophthalmic disease in large data sets: a systematic review.","volume":"40","author":"Hamedani","year":"2020","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"eoi240035r32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1097\/WNO.0000000000001805","article-title":"Accuracy of International Classification of Diseases codes for identifying acute optic neuritis.","volume":"43","author":"Muro-Fuentes","year":"2023","journal-title":"J Neuroophthalmol"},{"key":"eoi240035r33","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000002163","article-title":"Validity of administrative coding for nonarteritic ischemic optic neuropathy.","author":"Hamedani","year":"2024","journal-title":"J Neuroophthalmol"},{"key":"eoi240035r5","unstructured":"Novo Nordisk. Q1 2023 presentation, page 15. Accessed December 20, 2023. https:\/\/investor.novonordisk.com\/q1-2023-presentation\/?page=15"},{"key":"eoi240035r15","unstructured":"McPhillips? D. Prescriptions for popular diabetes and weight-loss drugs soared, but access is limited for some patients. CNN. September 27, 2023. Accessed December 13, 2023. https:\/\/www.cnn.com\/2023\/09\/27\/health\/semaglutide-equitable-access\/index.html"},{"key":"eoi240035r28","unstructured":"Office for Human Research Protections, US Department of Health and Human Services. Reviewing and reporting unanticipated problems involving risks to subjects or others and adverse events: OHRP guidance (2007). November 24, 2010. Accessed December 27, 2023. https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/guidance\/reviewing-unanticipated-problems\/index.html"}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/articlepdf\/2820255\/jamaophthalmology_hathaway_2024_oi_240035_1723584460.51198.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T11:02:23Z","timestamp":1723719743000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2820255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":33,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2024.2296","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,1]]}}}